Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites

Abstract

Dietary cholesterol drives NAFLD-HCC formation by inducing alteration of gut microbiota and metabolites in mice. Cholesterol inhibitory therapy and gut microbiota manipulation may be effective strategies for NAFLD-HCC prevention.